Beyond the Burden: Elevating Immunotherapy in Colorectal Cancer

Clinical Cancer Research 2026

View at publisher
Authors: Christine Megerdichian Parseghian, Madhulika Eluri
DOI: 10.1158/1078-0432.ccr-25-4251
Cited by: 0
References: 4

Abstract

Colorectal cancers treated with targeted therapies frequently acquire numerous subclonal genomic alterations. Tumor mutational burden (TMB) is under investigation as a biomarker for predicting response to immunotherapy in microsatellite-stable metastatic colorectal cancer. In this study, we contextualize a recent study evaluating high plasma TMB after targeted therapy and its implications for immunotherapy. See related article by Yeh et al., p. 1100.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Colorectal Cancer Treatments and Studies Genetic factors in colorectal cancer

Publication details

Journal / source
Clinical Cancer Research
Volume
32
Issue
6
Pages
999–1000
Publication date
13 January 2026
Language
EN